Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases.

Chao Y, Wu Q, Acquafondata M, Dhir R, Wells A.

Cancer Microenviron. 2012 Apr;5(1):19-28. doi: 10.1007/s12307-011-0085-4. Epub 2011 Sep 3.

2.

Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.

Toll A, Masferrer E, Hernández-Ruiz ME, Ferrandiz-Pulido C, Yébenes M, Jaka A, Tuneu A, Jucglà A, Gimeno J, Baró T, Casado B, Gandarillas A, Costa I, Mojal S, Peña R, de Herreros AG, García-Patos V, Pujol RM, Hernández-Muñoz I.

J Dermatol Sci. 2013 Nov;72(2):93-102. doi: 10.1016/j.jdermsci.2013.07.001. Epub 2013 Jul 15.

PMID:
23928229
3.

Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells.

Hong KO, Kim JH, Hong JS, Yoon HJ, Lee JI, Hong SP, Hong SD.

J Exp Clin Cancer Res. 2009 Feb 26;28:28. doi: 10.1186/1756-9966-28-28.

4.

Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.

Jeevan DS, Cooper JB, Braun A, Murali R, Jhanwar-Uniyal M.

Anticancer Res. 2016 Feb;36(2):523-32.

PMID:
26851006
5.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J.

Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25.

6.

Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition.

Chao YL, Shepard CR, Wells A.

Mol Cancer. 2010 Jul 7;9:179. doi: 10.1186/1476-4598-9-179.

7.

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.

Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J.

Cancer Res. 2008 Feb 15;68(4):989-97. doi: 10.1158/0008-5472.CAN-07-2017.

8.

Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β-catenin expression.

Umbreit C, Flanjak J, Weiss C, Erben P, Aderhold C, Faber A, Stern-Straeter J, Hoermann K, Schultz JD.

Anticancer Res. 2014 Dec;34(12):7061-9.

PMID:
25503133
9.

A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer.

Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noël A, Foidart JM, Birembaut P, Polette M, Gilles C.

Oncogene. 2012 Aug 16;31(33):3741-53. doi: 10.1038/onc.2011.540. Epub 2011 Nov 28.

PMID:
22120722
10.

Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.

Sethi S, Macoska J, Chen W, Sarkar FH.

Am J Transl Res. 2010 Oct 23;3(1):90-9.

11.

Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation.

Markiewicz A, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Majewska H, Szade J, Żaczek AJ.

Am J Transl Res. 2014 Nov 22;6(6):793-808. eCollection 2014.

12.

[Comparison of epithelial-mesenchymal transition-related markers between cancer tissue and tumor emboli].

He N, Wu GF, Zhao HY, Han HX.

Zhonghua Bing Li Xue Za Zhi. 2011 Nov;40(11):758-61. Chinese.

PMID:
22336160
13.

E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas.

Wells A, Yates C, Shepard CR.

Clin Exp Metastasis. 2008;25(6):621-8. doi: 10.1007/s10585-008-9167-1. Epub 2008 Jul 4. Review.

14.

A novel role of Id-1 in regulation of epithelial-to-mesenchymal transition in bladder cancer.

Hu H, Wang YL, Wang GW, Wong YC, Wang XF, Wang Y, Xu KX.

Urol Oncol. 2013 Oct;31(7):1242-53. doi: 10.1016/j.urolonc.2011.12.003. Epub 2012 Jan 5.

PMID:
22226665
15.

Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer.

Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S, Ueno S, Shinchi H, Natsugoe S.

J Surg Oncol. 2012 Jun 1;105(7):655-61. doi: 10.1002/jso.23020. Epub 2011 Dec 27.

PMID:
22213144
16.

Evidence of epithelial-mesenchymal transition in canine prostate cancer metastasis.

Fonseca-Alves CE, Kobayashi PE, Rivera-Calderón LG, Laufer-Amorim R.

Res Vet Sci. 2015 Jun;100:176-81. doi: 10.1016/j.rvsc.2015.03.001. Epub 2015 Mar 9.

PMID:
25796368
17.

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA.

Mol Cancer Res. 2011 Aug;9(8):997-1007. doi: 10.1158/1541-7786.MCR-10-0490. Epub 2011 Jun 10.

18.

Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II.

Mod Pathol. 2009 May;22(5):668-78. doi: 10.1038/modpathol.2009.19. Epub 2009 Mar 6.

19.

Dynamic molecular changes associated with epithelial-mesenchymal transition and subsequent mesenchymal-epithelial transition in the early phase of metastatic tumor formation.

Aokage K, Ishii G, Ohtaki Y, Yamaguchi Y, Hishida T, Yoshida J, Nishimura M, Nagai K, Ochiai A.

Int J Cancer. 2011 Apr 1;128(7):1585-95. doi: 10.1002/ijc.25500. Epub 2010 Jun 7.

20.

Differential membranous E-cadherin expression, cell proliferation and O-GlcNAcylation between primary and metastatic nodal lesion in colorectal cancer.

Jang TJ.

Pathol Res Pract. 2016 Feb;212(2):113-9. doi: 10.1016/j.prp.2015.12.003. Epub 2015 Dec 14.

PMID:
26724145

Supplemental Content

Support Center